Hydrogen peroxide therapeutic spray for protecting and treating mucosa

Abstract

The present invention relates to a therapeutic spray for protecting and treating mucosa, in particular nasal mucosa, against infection and allergy, and for protecting mucosa from oxidative damage caused by the use of a hydrogen peroxide nasal spray. The hydrogen peroxide spray acts through a redox reaction between hydrogen peroxide and mucous mucous or body fluid; however, it may cause damage to mucous membranes over a long period of time. The invention mitigates such lesions while providing therapeutic relief for a user suspected of infection or allergy. The present invention can utilize a hydrogen peroxide nasal spray to loosen mucus in the nasal cavity by oxidizing the mucus in the nasal cavity while enhancing delivery of one or more pharmaceutically acceptable compounds to the nasal mucosa by the energy of the redox reaction.

Description

[0001] Cross-reference to provisional application

[0002] This application utilizes U.S. Provisional Application No. 633109710, filed on March 2, 2022. Technical Field

[0003] The present invention relates to a therapeutic spray for protecting and treating mucous membranes, particularly nasal mucosa, from infection and allergies, and protecting the mucosa from oxidative damage caused by the use of hydrogen peroxide nasal sprays. Hydrogen peroxide sprays work through a redox reaction between hydrogen peroxide and mucosal mucus or body fluids; however, in the long term, it can cause damage to the mucosa. The present invention mitigates this damage while providing therapeutic relief to users who are suspected of infection or allergies. The present invention is able to utilize a hydrogen peroxide nasal spray to loosen mucus in the nasal cavity by oxidizing the mucus in the nasal cavity, while enhancing the delivery of one or more pharmaceutically acceptable compounds to the nasal mucosa through the energy of the redox reaction. The present invention minimizes the discomfort associated with the administration of hydrogen peroxide by gradually oxidizing the mucus or body fluids within 10-180 seconds. It protects the mucosa from the irritating effects of hydrogen peroxide using skin moisturizers and disclosed therapeutic compounds that penetrate into the mucosa through the energy of the redox reaction. The present invention is able to treat localized mucosa and enhance the delivery of drugs through the energy of the redox reaction for the treatment of various medical conditions in less than 3 minutes.

[0004] A directional spray bottle equipped with a metering pump is used to deliver a pharmaceutical composition with a viscosity of 1.1-1,000 centipoise, the pharmaceutical composition comprising hydrogen peroxide and one or more therapeutic compounds, the size of the atomized droplets being less than 100 microns, the pharmaceutical composition consisting essentially of 0.5%-3% weight / weight hydrogen peroxide, the therapeutic compound and deionized water. When the atomized droplets are applied to a mucosa, the atomized droplets form a substantially self-adhesive reactive coating (2') (less than 0.5 mm thick) therein Figure 1a ), thereby oxidizing the mucus or body fluid therein within 10-180 seconds, thereby loosening the mucus or body fluid from the mucosa, and at the same time, through the redox reaction energy between hydrogen peroxide and the mucus or body fluid, delivering the therapeutic compound and deionized water to the mucosa in less than 3 minutes.

[0005] One embodiment of the present invention relates to a pharmaceutical composition comprising hydrogen peroxide for use in a method of disinfecting nasal mucosa while protecting the nasal mucosa from oxidative damage caused by hydrogen peroxide. One embodiment of the present invention relates to a nasal spray system for disinfecting nasal mucosa while protecting the nasal mucosa from oxidative damage caused by redox reactions, and simultaneously providing therapeutic relief to a subject suspected of infection or allergy. One embodiment of the present invention relates to a method of disinfecting the mucosa of a subject suspected of infection or allergy through the energy of a redox reaction while protecting the mucosa from damage caused by a redox reaction, and simultaneously providing therapeutic relief. Background Art

[0006] Cleaning and disinfecting the nasal cavity and respiratory tract is essential for preventing and treating many allergies and viral infections, so it is also important to deliver therapeutic compounds and antimicrobial drugs to the mucosa. The traditional method of cleaning and disinfecting the nasal cavity is to rinse the nasal cavity with saline using a neti pot, as disclosed in the prior art: US20130041329A1 and US20130039950A1. Such methods are cumbersome because they require equipment, large amounts of water, and a sink. Once a viral infection is suspected, it must be treated immediately. This method may not be convenient for people who are away from home. Many pharmaceutically acceptable antimicrobial and therapeutic compounds are known, but they cannot fully penetrate into the mucosa when applied directly to the nasal cavity because the mucosa is usually covered with mucus or body fluids.

[0007] Viral infections are known to become trapped in the mucus lining the nasal cavity, but how to remove the infected mucus is less clear. Prior art has focused on killing the virus in situ in the mucus, often causing damage to the mucosa. The present invention takes a different approach to treating viral infections: it discloses a nasal spray for removing infected mucus from the nose while simultaneously delivering a drug compound to the mucosa, enabling disinfection and treatment in about 3 minutes. The present invention uses aerosolized droplets <100 microns in size, including hydrogen peroxide as an active agent, which loosens the mucus in the nasal cavity for removal, and exposes the mucosal surface to enable enhanced delivery of the disclosed drug compound to the mucosa. The inventor himself demonstrates one embodiment of the invention as a nasal spray in a posted video clip: www.gunkex.com / video1

[0008] Several hydrogen peroxide-based compositions are known, such as those disclosed in patents US4927627A, US4900721A, US6348187, US20220061320A1, EP2680818B1, AU2005244462B2, US8637085B2, CA2564763C, CA1277899C, US5665332A, US7060253B1, US5665332A and US7060253B1, but none discloses a nasal spray or drug delivery method for cleaning, disinfecting and treating the nasal cavity or mucosa. Despite the urgent need during the pandemic, no government agency, medical institution or manufacturer has proposed a system or method to clear infected mucus deep in the nasal cavity while being able to deliver antimicrobial compounds to the mucosa.

[0009] The closest prior art may be the applicant's own prior application US20220061320A1 (granted patent), which is limited to a specific composition. It should be noted that the provisional application of the present invention was filed before the publication of US20220061320A1 on March 3, 2022, so it may not be considered as prior art against the applicant.

[0010] Liquid hydrogen peroxide is known to be harmful to the nasal mucosa, so the FDA does not recommend its direct use. Using traditional methods such as neti pots to rinse the nasal cavity with a 3% hydrogen peroxide solution is cumbersome, harmful, and even fatal. (https: / / youtu.be / 5OowL-JuF1o). New Jersey State Government Website The New Jersey State Government website lists hydrogen peroxide as a hazardous substance and has several public warnings prohibiting its use in the nose or throat: https: / / tinyurl.com / 2p8jcyra

[0011] Currently, there is no data to prove the safety of long-term use of hydrogen peroxide on the nasal mucosa. The present invention has confirmed through clinical trials that hydrogen peroxide nasal spray itself not only harms the nasal mucosa after a few days of use, but also causes discomfort during use and has no therapeutic effect on the user. Figure 0xAn example of oxidative (redox) damage to mucous membranes caused by hydrogen peroxide when used alone is illustrated. In a clinical trial, 20 participants were asked to use a 1.5% hydrogen peroxide nasal spray twice a day for two weeks. It was found that the present invention discloses a method of protecting the mucous membranes from oxidative damage while providing therapeutic relief through the mucous membranes by topically applying hydrogen peroxide to the mucous membranes, especially the nasal mucosa. Despite the urgent need during the epidemic, no major manufacturer has launched a hydrogen peroxide-based nasal spray, and the U.S. Food and Drug Administration (FDA) has not recommended its use for such purposes. The present invention takes several creative steps to overcome the above-mentioned problems and proves that it can be safely used when mixed with the disclosed therapeutic compound and applied in the form of a fine mist aerosol. The inventor of the present invention has personally demonstrated the unexpected results in a video clip posted at the following website: www.gunkex.com / video1 Summary of the invention

[0012] Technical issues:

[0013] To protect the nasal mucosa from oxidative damage caused by topical application of hydrogen peroxide to the mucosa, particularly the nasal mucosa, and to achieve cleansing, disinfection and treatment of the nasal cavity to treat medical conditions by utilizing the energy of redox reactions to enhance the delivery of one or more pharmaceutically acceptable compounds to the mucosa in less than 3 minutes.

[0014] Problem Solution:

[0015] Although hydrogen peroxide is considered a hazardous substance, uncomfortable to use, and harmful to mucous membranes, the present invention has found that it can be used to clean, disinfect and treat the nasal cavity and mucous membranes, as well as to enhance drug delivery through the mucous membranes to treat various diseases while reducing its harmful effects. It discloses hydrogen peroxide for use in nasal sprays or mucosal spray devices, compositions, or methods for treating nasal disinfection, loosening mucus for removal from the nasal cavity, for nasal irrigation, or for dispersing one or more pharmaceutically acceptable compounds into the mucous membranes to treat medical conditions. The present invention discloses a number of means and methods for protecting the nasal mucosa from the damaging effects of the redox reaction between hydrogen peroxide and mucus or body fluids, while providing therapeutic relief to subjects suspected of infection or allergy. These means include droplet sizes of 100 microns or less, viscosity of the pharmaceutical composition, use of skin conditioning agents, and disclosed therapeutic compounds, which help to reduce such damage, reduce discomfort, and provide therapeutic relief.

[0016] The nasal mucosa is often covered in mucus, which prevents effective penetration of topical medications when administered in the form of nasal sprays. The present invention discloses a composition, method and device that can loosen mucus in about 10-180 seconds through hydrogen peroxide oxidation, while enhancing the delivery of drugs or therapeutic compounds into the mucosa through the energy of the redox reaction between hydrogen peroxide and mucus or body fluids. The loosened mucus can be drained or wiped away by the user. The system and method can clean, disinfect and treat, and can enhance the delivery of drugs through the mucosa to treat various diseases in less than 3 minutes.

[0017] The fine mist spray bottle is configured to produce atomized droplets less than 100 microns in size from a pharmaceutical composition containing hydrogen peroxide as an active delivery agent and at least one pharmaceutically acceptable delivery compound. When applied to the nasal cavity or mucous membrane, the atomized droplets oxidize the mucus or body fluids therein, thereby loosening the mucus or body fluids on the mucous membrane, while dispersing the delivery compound into the mucous membrane in less than 3 minutes through the energy of the redox reaction. This process is not only used to clean, disinfect and treat local mucous membranes, but also to deliver drugs into the body to treat various diseases.

[0018] The purpose of the present invention is to protect the mucous membranes from oxidative damage by hydrogen peroxide and to reduce the pain and discomfort associated with the administration of hydrogen peroxide. The present invention has found that the amount of hydrogen peroxide that contacts the mucous membranes in a given time is directly proportional to the pain and discomfort it causes. The present invention has found that when hydrogen peroxide is administered in the form of atomized droplets less than 100 microns together with skin moisturizers, pharmaceutical polymers and other therapeutic agents disclosed below, the harmful and uncomfortable effects of hydrogen peroxide on the nasal mucosa can be reduced. The use of skin moisturizers and polymers to increase the viscosity of the liquid solution can minimize the amount of hydrogen peroxide that contacts the mucous membranes in a given time, thereby being able to gradually oxidize the mucus, reduce pain and discomfort, and prevent damage to the nasal mucosa.

[0019] The present invention achieves a gradual redox reaction by a predetermined viscosity of the disclosed pharmaceutical composition. A gradual oxidation / reduction reaction can be achieved using a predetermined viscosity of 1.1-1,000 centipoise, wherein the transfer of electrons occurs between hydrogen peroxide and body fluids at a controlled rate; the released energy is dispersed over a longer period of time, such as 10-180 seconds. This allows for a more controlled release of energy over time, resulting in pain relief and controlled delivery of the disclosed compounds to the mucosa, prolonging their therapeutic effects while protecting the mucosa from damage caused by the sudden release of energy. When the disclosed skin moisturizers (e.g., glycerin, aloe gel, and pharmaceutical polymers) are used as a means of increasing viscosity and achieving mucosal adhesion to form a substantially self-adhesive reactive coating 2', protection against the damaging effects of hydrogen peroxide is further enhanced ( Figure 1a ).

[0020] In one embodiment of the present invention, the spray bottle used in the present invention consists of a metering pump configured to deliver about 0.05 ml to 0.2 ml of liquid solution per pump. The purpose is to inject only a predetermined amount of hydrogen peroxide into the nasal cavity per pump to minimize discomfort. For young healthy adults, it is generally found that about 0.15 mg of hydrogen peroxide is injected into each nasal cavity per pump. The term "about" refers to a 20% (±) variation. For two cavities, this amount is about 0.3 mg per pump. It is generally recommended to spray 2-3 times, with an interval of about 10-30 seconds, to reduce pain and discomfort, so the dose of hydrogen peroxide used each time is 0.6-1.2 mg. For children, the dose is preferably halved, and for domestic animals, the dose is preferably doubled. The above dosage is suitable for nasal application. For mucous membranes in other parts of the body, the dose should be doubled. The above dosage is calculated based on 1.5% hydrogen peroxide and using a 0.1 ml metering pump.

[0021] The present invention has found that only a thin self-adhesive reactive hydrogen peroxide coating (2') ( Figure 1a ), thickness <.5 mm, forming atomized droplets <100 microns in size, is sufficient to loosen the mucus and body fluids in the nasal cavity and mucosa and disperse the disclosed drug compounds into the mucosa. The present invention also found that the sudden oxidation of mucus in the nasal cavity by hydrogen peroxide (e.g., less than 10 seconds) is uncomfortable, while controlled gradual oxidation (e.g., 10-180 seconds) is acceptable to most healthy young people.

[0022] In order to achieve controlled or gradual oxidation of nasal mucus, the present invention utilizes glycerin, aloe vera gel, mucoadhesive polymers, surfactants, emulsifiers and thickeners to enable the atomized droplets to adhere to the mucosa for 10-180 seconds without dripping in large quantities, thereby forming a reactive coating (2') with a thickness of less than 0.5 mm. In one embodiment of the present invention, a liquid solution viscosity of 1.1-1,000 centipoise is used as a means to minimize dripping and achieve a controlled gradual redox reaction. The thickness of the reactive coating (2') and the size of the droplets used depend on the mucoadhesive polymers, surfactants, emulsifiers, alcohols, astringents or thickeners used. For example, a reactive coating (2') based primarily on hydrogen peroxide, monoterpenoids, alcohols and astringents can be 0.1 mm thick and the droplet size can be 1-30 microns. When aloe vera gel, mucoadhesive polymers and / or thickeners are used to increase viscosity, the droplet size can be 20-100 microns (VMD) to ensure a smooth flow of the spray, and the thickness of the reactive coating (2') is 0.1-1 mm thick. The required thickness of 0.5 mm is the average thickness of the coating; it will vary between about 0.01-1 mm. The above measurements are for reference only, and they are not intended to limit the scope of the present invention, as these measurements depend on several other factors, such as the number of sprays, the dryness of the individual's nasal cavity, and environmental factors such as temperature and humidity. Since the droplets move with gravity when applied, they may accumulate in the nooks and crannies of the mucosa, causing the reactive coating (2') to become thicker in some places as well. The coating measurements provided herein are average values ​​at the time of application. Due to the redox reaction, these measurements begin to change immediately after the reactive coating (2') is applied. In addition, since the degree of discomfort varies from person to person, and the present invention is also applicable to domestic animals, the time duration measurements provided herein are for reference only. The droplet size is less than 100 microns, the viscosity of the liquid solution is 1.1-1000 centipoise, and the mucoadhesion method, such as electrostatic deposition, diffusion, adsorption and / or hydrogen bonding of fine droplets to the mucosa using the disclosed surfactants, alcohols, astringents, solubilizers, mucoadhesives, polymers and thickeners, all help to form a self-adhesive reactive coating (2') with a thickness of less than 0.5 mm, thereby allowing a gradual redox reaction between hydrogen peroxide and mucus or body fluids.

[0023] To mask the discomfort of injecting hydrogen peroxide into the nasal or oral cavity, the present invention utilizes fragrances and flavorings that also provide therapeutic relief. To mitigate the harmful effects of hydrogen peroxide on mucous membranes, the present invention utilizes skin moisturizers and humectants, such as glycerol (glycerin) or its derivatives, aloe gel, and pharmaceutically acceptable polymers. In one embodiment of the present invention, the present invention utilizes therapeutic compounds, such as soda water and citric acid, so that hydrogen peroxide droplets can gradually control oxidation while providing therapeutic relief. For domestic animals, no fragrances or flavorings are required.

[0024] The object of the present invention is to treat local diseases associated with mucosa, and to enhance the drug delivery of drug compounds through mucosa to treat various diseases, such as delivering drugs to the central nervous system (CNS). In one embodiment of the present invention, atomized droplets containing hydrogen peroxide with a size less than 100 microns are used to deliver therapeutic salts, local steroids, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), analgesic compounds, antibiotic compounds and local anesthetic compounds are passed through the mucosa in the form of nasal sprays or throat sprays. In one embodiment of the present invention, drugs specific to gum sprays, ear sprays or for treating the urinary tract are delivered by the energy of redox reactions. Many of these drugs are marked by chemical structures comprising one or more five-membered rings, six-membered heterocycles or combinations thereof. The present invention finds that hydrogen peroxide is compatible with delivering compounds marked by the above chemical structures as an active agent, particularly when the compound also contains oxygen, nitrogen, sulfur or phosphorus or a combination thereof in the chemical structure.

[0025] When hydrogen peroxide atomized droplets less than 100 microns are sprayed into the mucous membrane, tiny clusters of active oxygen bubbles are formed1'( Figure 1b ), these oxygen bubble clusters can act as carriers to disperse the disclosed drug compounds into the mucosa by mechanical action. These carriers are driven by the energy of the redox reaction, allowing the disclosed compounds to penetrate deeper into the mucosa.

[0026] The disclosed nasal spray and oral spray devices provide a convenient and quick method to clean, disinfect and treat the nasal cavity and mucous membranes without bulky equipment, thereby minimizing the risk of viral infection immediately when it is suspected. The device and method provide a preventive measure against viral infection, an emergency treatment system for viral infection, and the delivery of drugs to the mucous membranes to treat various diseases. The method includes the following steps:

[0027] (1) Spraying atomized droplets with a particle size of less than 100 microns (containing 0.25%-3% w / w hydrogen peroxide, one or more pharmaceutically acceptable deliverable compounds and deionized water) into the nasal cavity or mucosa

[0028] (2) Forming a reactive coating of atomized droplets with a thickness of less than 0.5 mm in the nasal cavity or on the mucous membrane (2')

[0029] (3) Allow the atomized droplets to react with the mucus in the nasal cavity or mucosa for 10 to 180 seconds.

[0030] As a result, the aerosolized droplets oxidize the mucus in the nasal cavity through the energy of the redox reaction in less than 3 minutes, loosening the mucus for removal while dispersing the pharmaceutically acceptable deliverable compound into the mucosa.

[0031] The term 'self-adhesive reactive coating (2')' refers to a property of the atomized droplets wherein at least 50% of the applied droplets adhere to the inner surface of the nasal cavity for at least 10 seconds without dripping. This is achieved by the glycerin, aloe vera gel, mucoadhesive, polymeric surfactant or astringent disclosed herein. Glycerin, aloe vera gel, mucoadhesive and pharmaceutical polymers are used to achieve a viscosity of 1.1-1,000 centipoise, which allows the mucus to be gradually oxidized over 10-180 seconds, thereby minimizing discomfort; this is in contrast to the sudden oxidation when hydrogen peroxide is used as a nasal spray by itself, resulting in greater discomfort and damage to the nasal mucosa.

[0032] The object of the present invention is to minimize the decomposition of hydrogen peroxide and to promote the economical utilization of materials used in the disclosed nasal spray or mucosal spray. To achieve these goals, the present invention discloses retail packaging options for nasal spray or mucosal spray, such as Figure 2a , 2b shown and described below.

[0033] It is an object of the present invention to achieve targeted drug delivery, thereby minimizing the harmful effects of antimicrobial agents. For example, one embodiment of the present invention is a dental spray containing 2%-3% hydrogen peroxide, chlorhexidine gluconate .01-.2% and an aromatic compound or flavor. This dental spray can target the specific gums of the user that need treatment using only .1 to .2 ml of liquid solution in one or two sprays. This is in stark contrast to a mouthwash that uses about 5 ml of the same solution to achieve the same effect and exposes the entire mouth to the harmful effects of chlorhexidine gluconate. In addition, chlorhexidine gluconate is delivered deeper into the mucosa through the energy of the redox reaction.

[0034] Beneficial effects of the present invention:

[0035] The aerosolized nasal spray or mucosal spray of the present invention can be conveniently sprayed into the nasal cavity or onto the mucosa, thereby enabling cleaning, disinfection and treatment in less than three minutes without the use of bulky equipment such as a neti pot or sink. The nasal spray bottle of the present invention is essentially a device that removes infected mucus from the nasal cavity and provides therapeutic relief in less than 3 minutes. The disclosed systems and methods are capable of removing infected mucus from the nasal cavity to prevent viral infection while delivering therapeutic compounds to the mucosa. The disclosed mucosal spray provides therapeutic relief through the energy of redox reactions and is capable of enhancing drug delivery through the mucosa to treat a variety of diseases. The use of the present invention is also applicable to domestic animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 0x An example of oxidative damage to the mucosa by hydrogen peroxide is shown.

[0037] Figure 1aA schematic cross-sectional view of a mucous membrane is shown. It shows that when the atomized droplets are sprayed on the mucous membrane, a self-adhesive reactive coating 2' is formed. This results in the formation of tiny reactive oxygen bubble clusters (1'). The reactive oxygen bubbles 1' move by mechanical transport, using the energy generated by the oxidation / reaction between hydrogen peroxide and the mucous and body fluids of the mucous membrane ( Figure 1b ). Mechanical conveying refers to Figure 1b The movement of active microscopic oxygen bubbles (1') on the mucosa is shown in . This movement is driven by the energy generated by the redox reaction between hydrogen peroxide and the mucous and body fluids of the mucosa. The active oxygen bubbles (1') promote the delivery of drugs through mechanical movement. This movement is due to the energy released by the redox reaction between hydrogen peroxide and the mucosal fluid, which provides an energy driving force for the movement of the bubbles. In addition, this also enables the deliverable compound to be actively transported (ATP) to the cell membrane protein through the energy of the redox reaction through the movement of the active microscopic oxygen bubbles (1'), thereby further enhancing the delivery of the compound. A non-limiting example of the movement of active microscopic oxygen bubbles (1') can be seen in the following video clip: www.gunkex.com / video1.

[0038] Figure 1b This is a microscopic snapshot of an active microscopic oxygen bubble microcluster (1').

[0039] Figure 2a , 2b Retail packaging options for nasal sprays and mucosal sprays for cleaning, disinfecting and treating the nasal cavity or mucous membranes are shown.

[0040] Figure 3a , 3b Examples of heterocyclic compounds are shown. DETAILED DESCRIPTION

[0041] The present invention utilizes hydrogen peroxide in different ways to achieve nasal disinfection, nasal irrigation and delivery of various therapeutic compounds and drugs to the mucosa through the energy of redox reactions generated when oxidizing mucus, enzymes and impurities present in mucosal body fluids. The present invention discloses various means and methods to protect the nasal mucosa from the harmful effects caused by redox reactions while providing therapeutic relief to subjects suspected of infection or allergy. The present invention has found that a thin coating (2') of less than .5 mm thickness formed by a fine mist of hydrogen peroxide with droplets <100 microns in size composed of 0.5%-3% w / w hydrogen peroxide and deionized water delivered by a directional spray bottle is sufficient to loosen and clear mucus in the nasal cavity while dispersing hydrogen peroxide droplets and deionized water into the mucosa for nasal disinfection and irrigation while mitigating the harmful effects of redox reactions. In different embodiments of the present invention, additional therapeutic compounds are added to the aqueous solution to further enhance the therapeutic value, user experience and treatment of various diseases. The unexpected results achieved by the present invention are demonstrated by the inventors in the video clips posted below: www.gunkex.com / video1.

[0042] In one embodiment, the present invention relates to a pharmaceutical composition consisting essentially of hydrogen peroxide and glycerin or a moisturizer, used as a medicament for protecting mucosa from oxidative damage, when applied in aerosolized droplets less than 100 microns, for treating medical conditions. In one embodiment, the present invention relates to an aerosolized composition consisting essentially of hydrogen peroxide, glycerin or a skin moisturizer, a therapeutic compound and deionized water, for use in a method of protecting nasal mucosa from oxidative damage while being able to treat medical conditions. One embodiment of the present invention is: hydrogen peroxide, used in a composition for dispersing one or more pharmaceutically acceptable compounds into the mucosa. One embodiment of the present invention is: hydrogen peroxide, used in a method for relieving nasal congestion. In one embodiment of the present invention, hydrogen peroxide is used in a nasal spray or mucosal spray device, a composition or a method for nasal disinfection treatment, loosening mucus for removal from the nasal cavity, for nasal irrigation, or for dispersing one or more pharmaceutically acceptable compounds into the mucosa to treat medical conditions. The fine mist spray bottle is configured to generate aerosolized droplets less than 100 microns in size from a pharmaceutical composition containing reactive oxygen species (ROS) such as hydrogen peroxide as an active delivery agent and at least one pharmaceutically acceptable deliverable compound. When applied to the nasal cavity or mucosa, the aerosolized droplets oxidize the mucus or body fluid therein, thereby loosening the mucus or body fluid from the mucosa, while dispersing the deliverable compound into the mucosa in less than 3 minutes through the energy of the redox reaction.

[0043] The present invention discloses a nasal spray or mucosal spray for cleaning, disinfecting and treating the nasal cavity or mucosa and delivering various pharmaceutical compounds to the mucosa in less than 3 minutes. The system is mainly composed of a fine mist spray bottle, which is configured to produce an aerosol droplet size of less than 100 microns, a pharmaceutically acceptable peroxide, the oxidation state of which is O -1 ; one or more pharmaceutically acceptable deliverable compounds; and deionized water. When administered as a nasal spray or mucosal spray, the aerosolized droplets form a reactive coating (2') less than 0.5 mm thick on the mucosa, oxidizing the mucus or enzymes therein for 10-180 seconds, loosening the mucus or body fluids from the mucosa, thereby dispersing the deliverable compounds into the mucosa through the energy of the redox reaction. During the redox reaction, microscopic oxygen bubbles 1'( Figure 1a , 1b ) to disperse the deliverable compound and deionized water into the mucosa.

[0044] In one embodiment of the present invention, the fine mist spray bottle is configured to produce a directional spray of atomized droplets less than 100 microns in size from a liquid solution consisting of 0.5%-3% weight / weight hydrogen peroxide and deionized water. When the atomized droplets are sprayed into the nasal cavity, they form a reactive coating (2') less than 0.5 mm thick therein, loosening the mucus by oxidizing the mucus within 10-180 seconds for removal from the nasal cavity, while the deionized water is dispersed into the mucosa by the energy of the redox reaction, thereby enabling disinfection and flushing of the nasal cavity in less than three minutes. In order to further reduce discomfort and enhance the therapeutic value and treatment options, different additional substances are added, as described below.

[0045] In one embodiment of the present invention, the nasal spray or mucosal system is mainly composed of a fine mist. The directional spray bottle is configured to produce atomized droplets less than 100 microns in size from a liquid solution with a viscosity of about 1.1-1,000 cP (centipoise), the liquid solution mainly consisting of one or more pharmaceutically acceptable peroxides. 25%-5% w / w; one or more aromatic compounds. 005%-5% w / w; one or more skin moisturizers, moisturizers or mucoadhesive polymers, emulsifiers, solvents or surfactants. 1%-30% w / w; and deionized water. When applied, the atomized droplets basically adhere to the inner wall of the nasal cavity or mucosa, and basically will not drip for at least 10 seconds, forming a reactive coating (2') with a thickness of less than 0.5 mm. The atomized droplets oxidize the mucus or body fluids therein within 10-180 seconds, loosening the mucus or body fluids from the mucosa, while dispersing the aromatic compounds, skin moisturizers, moisturizers and mucoadhesive polymers into the mucosa, thereby achieving cleaning, disinfection and treatment. In one embodiment of the invention, the liquid solution is further composed of benzalkonium chloride, benzoic acid, boric acid, chlorhexidine gluconate, cetylpyridinium chloride (CPC) or a pharmaceutically acceptable cationic surfactant. In one embodiment of the invention, the liquid solution is further composed of sodium bicarbonate, magnesium sulfate, aluminum sulfate, sodium borate, sodium benzoate, sodium phosphate, sodium salicylate, sodium peroxide carbonate, sodium percarbonate, sodium citrate or sodium carboxymethylcellulose. In one embodiment of the invention, the liquid solution is also composed of preservatives, topical steroids, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), analgesic compounds, antibiotic compounds, antipruritic compounds, local anesthetic compounds or central nervous system (CNC) agents, with a weight percentage of 0.01%-5%. In one embodiment of the invention, the liquid solution is also composed of 5%-50% v / v of alcohol. All preparations contain pharmaceutically acceptable preservatives, stabilizers, chelating agents or buffers to ensure the predetermined shelf life of the preparation.

[0046] One embodiment of the present invention is a nasal spray comprising a nasal spray bottle configured to produce aerosolized droplets <100 microns in size, made from a liquid solution comprising hydrogen peroxide. 25%-3% w / w; one or more aromatic or flavoring compounds. 005%-5% w / w; one or more skin moisturizers, humectants, mucoadhesive polymers, emulsifiers, solvents or surfactants. 1%-30% w / w; and deionized water. When the aerosolized droplets are injected into the nasal cavity, a thin coating (2') having an average thickness of <1000 microns is formed on the mucous membrane therein, oxidizing the mucus for 10-180 seconds, loosening the mucus for removal, and simultaneously dispersing the aromatic or flavoring compound, skin moisturizer, humectant, mucoadhesive polymer, emulsifier, solvent or surfactant into the mucous membrane. Dispersion of the deliverable compound is by energy or redox reaction and the formation of active microscopic oxygen bubbles 1'( on the mucous membrane during oxidation Figure 1a , 1b In one embodiment, the liquid solution further comprises an effective amount of an antiseptic, a topical steroid, an antihistamine, a nonsteroidal anti-inflammatory drug (NSAID), an analgesic compound, an antibiotic compound, an antipruritic compound, a local anesthetic compound, or a central nervous system drug (CNC).

[0047] One embodiment of the present invention is a nasal spray or mucosal spray, comprising a fine mist spray, the fine mist spray comprising aerosolized droplets of less than 100 microns in size, comprising 0.25% to 3% weight / weight hydrogen peroxide; 0.005%-2.5% weight / weight of one or more aromatic compounds; about 0.1% to 30% glycerol, glycerol derivatives, aloe gel or mucoadhesive polymers; and deionized water. In one embodiment of the present invention, the aerosolized droplets also include 5%-50% v / v ethanol.

[0048] One embodiment of the present invention is a nasal spray, comprising a fine mist spray, the fine mist spray comprising aerosol droplets of size <100 microns, including .25% to 5% w / w hydrogen peroxide; chlorhexidine gluconate .01%-1%; one or more aroma or flavor compounds 0.005%-5% w / w; and deionized water. When applied, the aerosolized droplets oxidize and loosen the mucus or body fluids on the mucosa, while dispersing the chlorhexidine gluconate and the aroma or flavor compounds into the mucosa through the energy of the redox reaction.

[0049] One embodiment of the present invention is a mucosal spray, comprising a fine mist spray, the fine mist spray comprising aerosol droplets of size <100 microns, including .25% to 5% w / w hydrogen peroxide; borax .1%-5%; glycerol, glycerol derivatives or mucoadhesive polymers about 0.1%-30%; and deionized water. When applied, the atomized droplets oxidize and loosen the mucus or body fluids on the mucosa through the energy of the redox reaction, while dispersing the borax, glycerol, glycerol derivatives or mucoadhesive polymers into the mucosa.

[0050] In one embodiment of the present invention, a method for cleaning, disinfecting and treating the nasal cavity or mucous membrane comprises the following steps:

[0051] (1) Spraying atomized droplets with a size of less than 100 microns into the nasal cavity or onto the mucous membrane, wherein the droplets contain 0.25%-3% w / w hydrogen peroxide, one or more pharmaceutically acceptable deliverable compounds in Group 1, and deionized water. Group 1 includes:

[0052] at least one aromatic or flavoring agent.005%-5% w / w;

[0053] at least one skin moisturizer or humectant. 1%-30% w / w;

[0054] at least one pharmaceutically acceptable mucoadhesive polymer, surfactant, emulsifier or thickener. 1%-10% w / w;

[0055] (2) forming a reactive coating (2') of the aerosolized droplets in the nasal cavity or on the mucosa, and allowing the aerosolized droplets to react with the mucus in the nasal cavity or on the mucosa for at least 10 seconds. The aerosolized droplets oxidize the mucus, loosen the mucus for removal, and disperse the pharmaceutically acceptable deliverable compound from Group 1 into the mucosa in less than 3 minutes.

[0056] The present invention mainly utilizes stable hydrogen peroxide or food grade hydrogen peroxide. 25%-5% w / w as the active delivery agent. The use of other pharmaceutically acceptable peroxides or oxidants, such as urea-hydrogen peroxide, benzoyl peroxide, sodium percarbonate, is within the scope of the present invention. In one embodiment of the present invention, the aerosolized droplets include a combination of hydrogen peroxide and urea-hydrogen peroxide or benzoyl peroxide as the active delivery agent. The active delivery agent is used to deliver one or more pharmaceutically acceptable deliverable compounds. When administered in the form of aerosolized droplets, the oxidation state of the active delivery agent is O -1 ; This indicates that the peroxide does not decompose when mixed with the deliverable as a liquid and is active for the intended oxidation of mucus and body fluids. The peroxide and / or hydrogen peroxide used in the present invention typically include chemical stabilizers, buffers, chelating compounds and catalytic inhibitors, such as sodium phosphate, sodium phytate, phosphoric acid, phosphorous acid, acetanilide, sodium stannate, tin derivatives and / or disodium ethylenediaminetetraacetic acid (EDTA).

[0057] The pharmaceutical composition disclosed in one embodiment of the present invention is pre-packaged in a fine mist spray bottle, while in another embodiment, the pharmaceutical composition is packaged in a separate container, allowing the user to fill or refill the fine mist spray bottle as needed. In one embodiment of the present invention, in order to extend the shelf life of hydrogen peroxide and pharmaceutically acceptable deliverable compounds, they are packaged in separate containers; the user can combine these ingredients as needed. The above-mentioned spray bottle and liquid container can be packaged into a single retail package or can be packaged into separate retail packages. The above-mentioned configuration enables economical utilization of the components of the system for treating the nasal cavity, respiratory tract and mucous membranes. Figure 2a , 2bAn embodiment of the present invention is shown in the form of a nasal cleaning and disinfecting system 101 and 102. System 101 includes a retail package 101a, which is composed of a nasal spray bottle 101b and a liquid container 101c. Nasal spray bottle 101b can be pre-filled with a liquid solution containing hydrogen peroxide and a pharmaceutically acceptable deliverable compound, or can be empty so that the user can fill the above liquid solution from container 101c when needed. System 102 includes a retail package 102a, which is composed of a nasal spray bottle 102b, a liquid container 100b and a liquid container 102d. Liquid container 102c is filled with a combination of stabilized hydrogen peroxide.210%-10% w / w or a pharmaceutically acceptable peroxide.210%-10% w / w and deionized water. Liquid container 102d is filled with one or more pharmaceutically acceptable deliverable compounds. The method of using system 102 includes mixing the formulations in containers 102c and 102d in a predetermined ratio and filling the mixture into nasal spray bottle 102b when needed.

[0058] One of the challenges facing compositions containing peroxides is how to maintain their integrity when mixed with a deliverable agent, since peroxides tend to oxidize most substances and decompose in the process. The present invention has found that five- or six-membered heterocyclic rings in the chemical structure of peroxide-containing drug compounds are generally compatible with hydrogen peroxide, thereby enhancing its delivery to the mucosa. The compounds used in the present invention generally do not contain transition metals (Groups 3-12) because they decompose peroxides. The present invention utilizes chemical buffers, inhibitors, or chelators to maintain the integrity of hydrogen peroxide, even if they are not explicitly stated as such. The following are non-limiting examples of pharmaceutically acceptable therapeutic compounds and drugs. As a reference to the claims, they are divided into several groups; however, these groups do not represent scientific or chemical classifications. Several substances listed in these groups have multiple uses, so when multiple groups are listed in a single claim, it should be considered to make the claim unclear. Compounds that are incorrectly defined or classified in this application can be omitted without affecting the scope of the invention:

[0059] Group (a): pharmaceutically acceptable heterocyclic compounds. Figure 3a and 3bSome examples of such compounds are shown. In one embodiment of the invention, the heterocyclic compound is identified by its chemical structure, which contains one or more five-membered heterocycles, one or more six-membered heterocycles, or a combination thereof. The heterocyclic compound used in the present invention contains at least one nitrogen (N), oxygen (O), sulfur (S) or phosphorus (P) heteroatom in its chemical structure. Some examples are furans, indoles and / or purines, which are used as the backbone and building blocks of many drugs. Many heterocyclic derivatives and substituted heterocyclic groups incorporating various heteroatoms are known in the art, such as those identified by patents: US20060293320A1, US8729077B2, US8394968B2 and US8143414B2. Some examples are aromatic compounds, monoterpenoids, alcohols, phenols and derivatives thereof. Drugs and substances such as acetaminophen, aspirin, benzocaine, hydroxyzine, chloroxylenol, chlorflucarban, bacitracin, salicylic acid, chlorhexidine gluconate, nicotinamide, cannabis, caffeine and nicotine. Central nervous system (CNS) stimulants such as armodafinil and modafinil. Nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, antipruritics, analgesic compounds, antihistamines, antibiotics, antiseptics, local anesthetics, steroids, antifungal agents such as azoles and azole derivatives, nucleic acids containing the above chemical structures or substructures, vitamins and vaccines.

[0060] Group (b): Pharmaceutically acceptable aromatic compounds, monoterpenes, terpenoids. 005%-5% w / w such as aromatic and therapeutic substances in essential oils. Some examples are: phenolic monoterpenes such as thymol, carvacrol, eugenol. 005%-1% w / w. Effective amounts of methyl salicylate, eucalyptol, geraniol, menthol, raspberry ketone, p-pinene, cinnamaldehyde, salicylic acid, nootkatone, terpineol, α-terpineol, limonene, borneol, terpinen-4-ol, camphor, cannabidiol (CBD), cresol, phenol or derivatives of the above compounds. Although some substances (such as camphor) do not meet the chemical classification of aromatics, in the context of the present invention, these substances are considered aromatics because they are part of monoterpenes. Pharmaceutically acceptable flavoring compounds. 1%-10% w / w, such as geranyl acetate, methyl formate, ethyl acetate, jasmone, benzaldehyde, vanillin, anethole and benzenediol, spore alkane and spore amine. Synthetic flavors. Aromatic compounds dissolved in pharmaceutically acceptable solvents, ethanol, dimethyl sulfoxide (DMSO), solubilizers, emulsifiers and / or surfactants for uniform distribution through open aerosol droplets. Some examples include sugar alcohols, such as sorbitol, mannitol, erythritol, maltitol and xylitol. Aromatic compounds and flavors identified in the U.S. Food and Drug Administration (FDA) Inactive Ingredient Database (July 2022): https: / / tinyurl.com / 57yxyxjw.

[0061] Group (c): pharmaceutically acceptable skin moisturizers or humectants. 1%-30% w / w, for example: aloe vera gel, glycerol (glycerol) or its derivatives, such as polyglycerol, monoglyceride and diglyceride. Pharmaceutically acceptable polymers or polyols, such as hydrophilic polymers, polyethylene glycol (PEG) or its derivatives (PPG), such as PEG-40, propylene glycol (PG) or its derivatives and copolymers. Hydroxy acids, such as alpha-hydroxy acids (AHA, BHA); hydrophilic silicon polymers and silica aerogels. Hyaluronic acid, salicylic acid, sodium lactate, sodium PCA or lactic acid. Urea and its derivatives, such as hyaluronic acid urea, allantoin (10-ureidohydantoin) and imidazolidinyl urea. Polydimethylsiloxane. Vitamin A, vitamin B3, D-panthenol, pantothenic acid and vitamin E. Peptides and amino acids. Hydrogenated castor oil, lanolin oil, hydrogenated lanolin, paraffin, paraffin oil. Ceramide and collagen. Glycolic acid, ascorbic acid, citric acid. Pharmaceutically acceptable polymers. 1%-30% w / w. Skin care excipients such as emollients and occlusives. https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC410010343 /

[0062] Group (d): pharmaceutically acceptable polymers. 1%-30% w / w, for example: mucoadhesives, gelling agents, thickeners or p-polyethylene glycol (PEG) or its derivatives (PPG), such as PEG-40. Cellulose derivatives with carboxymethyl (-CH2-COOH), carboxymethyl cellulose (CMC), cellulose gum, xanthan gum, EmulthixTM, disodium edetate, carbomer, sodium carboxymethyl cellulose (SCMC), hydrogels, polysaccharide polymers and their derivatives, acrylates, carrageenan, gellan gum, polyacrylic acid, glycerol (glycerol) or its derivatives, aloe vera gel, hyaluronic acid, poly (acrylic acid) polymers, poly (hydroxyethyl methacrylate), poly (ethylene oxide), polyvinyl pyrrolidone, polyvinyl alcohol, chitosan and its derivatives. Poloxamers, poloxamer 407. Hydrophilic polymers. Mucus active agents, such as mucolytic agents. https: / / tinyurl.com / 2fwptvpz

[0063] Group (e): alcohols, for example, ethanol, isopropanol, cetyl alcohol, aromatic alcohols, sugar alcohols, benzyl alcohol.

[0064] Group (f): pharmaceutically acceptable surfactants, emulsifiers, solubilizers or astringents. 01%-1% such as: non-ionic, anionic, cationic or amphoteric surfactants such as: cetyltrimethylammonium ('cetrimide'), chlorhexidine and its derivatives such as chlorhexidine gluconate, chlorhexidine acetate, xylenol, chloroxylenol, benzalkonium chloride, cetylpyridinium chloride, cetylpyridinium chloride (CPC), polysorbate-20, polysorbate-80, polyoxyethylene, glycosides, cremophor RH 40 and derivatives of oxygen-containing quaternary ammonium compounds. Bile acids. Lipids and phospholipids; palmitic acid, stearic acid, oleic acid, linoleic acid. Self-emulsifying drug delivery systems (SEDDS). Alum and its derivatives, witch hazel, dimethyl sulfoxide (DMSO). Mucoactive agents, such as mucolytics.

[0065] Group (g): Pharmaceutically acceptable therapeutic salts, such as organic salts. Pharmaceutically acceptable sodium salts, such as sodium bicarbonate, sodium borate, sodium benzoate, sodium fluoride, sodium phosphate, sodium salicylate, sodium carbonate peroxide, sodium percarbonate, sodium citrate, sodium carboxymethylcellulose and sodium phytate. Alum and its derivatives. Magnesium sulfate, zinc gluconate, carboxylates and benzethonium chloride. https: / / en.wikipedia.org / wiki / Oxyanion|https: / / tinyurl.com / 2p8kpvny

[0066] The therapeutic compounds and drugs in different material combinations groups (a)-(g) can be combined to formulate a pharmaceutical composition or emulsion, which is used to produce an aerosolized composition by using the directional spray bottle of the present invention. The pharmaceutical composition can be a microemulsion or nanoemulsion group containing one or more of the above ingredients.

[0067] A combination of viscosity 1.1-1,000, droplet size <100 microns, use of mucoadhesives and polymers (which can also be used as skin moisturizers), use of surfactants and alcohols, etc. can form a substantially self-adhesive reactive coating with a thickness of less than 0.25 microns, which can gradually oxidize mucus within 10 to 180 seconds, thereby loosening the mucus or body fluids from the mucosa, and at the same time can deliver the disclosed drug compounds to the mucosa in less than 3 minutes through the energy of the redox reaction between the hydrogen peroxide and the body fluids.

[0068] The term "consisting essentially of..." in the context of the present invention excludes all substances in the prior art that do not play the positive role disclosed by the present invention. However, the term "consisting essentially of..." in the context of the present invention includes substances that extend the shelf life of the disclosed pharmaceutical composition, such as preservatives, stabilizers and chemical buffers. The term "microclusters of active microscopic oxygen bubbles" is used to describe random clusters of active oxygen bubbles formed arbitrarily. The term "sufficient amount" refers to a pharmaceutically acceptable amount that provides therapeutic relief to treat a medical condition, or an amount suitable as a preventive measure or treatment. The systems and methods disclosed herein are suitable for treating mucous membranes in all parts of the body, such as the throat, mouth, respiratory tract, gums, ears and genitals. In one embodiment of the present invention, the above-mentioned systems and methods are used to treat hair follicles, open wounds, disinfection of body parts during surgery, damaged skin, etc. The droplet size provided in microns refers to the volume mean diameter (VMD). Viscosity measurements are performed at room temperature 21°C.

[0069] This application includes several examples that provide hyperlinks for additional information. However, since these external hyperlinks may change, they are for reference only. They are not part of this application. The embodiments of the present invention described herein are for example only and should not be interpreted in a limiting sense as to the scope of the present invention. Different embodiments of the present invention can be combined to develop other embodiments. Any embodiment developed by extrapolating or combining the compositions, drug delivery methods, devices and systems disclosed herein is within the scope of the present invention.

Claims

1. A pharmaceutical composition for nasal spray for disinfecting nasal mucosa while protecting the nasal mucosa from oxidative damage caused by hydrogen peroxide, the pharmaceutical composition having a viscosity of 1.1-1,000 centipoise and consisting mainly of the following ingredients: Hydrogen peroxide 0.5%-3% w / w; Skin moisturizer; and Deionized water, It is characterized in that when the pharmaceutical composition is sprayed onto the nasal mucosa in the form of atomized droplets less than 100 microns using a nasal spray bottle, a substantially self-adhesive reactive coating with a thickness of less than 0.5 mm is formed on the nasal mucosa and at least a portion of the mucus of the nasal mucosa can be gradually oxidized between 10 and 180 seconds, thereby loosening the at least a portion of the mucus from the nasal mucosa, and at the same time, the skin moisturizer and the deionized water are transported to the nasal mucosa by utilizing the energy of the redox reaction between the hydrogen peroxide and the at least a portion of the mucus.

2. The pharmaceutical composition for nasal spray according to claim 1, wherein the skin moisturizer is at least one of the following substances: glycerol and its derivatives.

3. The pharmaceutical composition for nasal spray according to claim 1, wherein the skin moisturizer is at least one of the following substances: aloe vera gel, sodium lactate, urea, urea derivatives, polymers and copolymers.

4. The pharmaceutical composition for nasal spray according to claim 1, wherein the pharmaceutical composition also consists essentially of at least one of the following substances: an aromatic compound and a flavoring compound.

5. The pharmaceutical composition for nasal spray according to claim 1, wherein the pharmaceutical composition also consists essentially of a pharmaceutically acceptable heterocyclic compound.

6. The pharmaceutical composition for nasal spray according to claim 1, wherein the pharmaceutical composition also consists essentially of at least one of the following substances: alcohol, a surfactant, an astringent, cetylpyridinium chloride and chlorhexidine gluconate (CHG).

7. The pharmaceutical composition for nasal spray according to claim 1, wherein the pharmaceutical composition is also essentially composed of at least one of the following substances: borax, boric acid, magnesium sulfate, alum and pharmaceutically acceptable sodium salts.

8. The pharmaceutical composition for nasal spray according to claim 7, wherein the pharmaceutical composition is also essentially composed of at least one of the following substances: an aromatic compound, a flavoring compound, a pharmaceutically acceptable heterocyclic compound, an alcohol, a surfactant, an astringent, cetylpyridinium chloride and chlorhexidine gluconate (CHG), The skin moisturizing agent is at least one of the following: glycerin, glycerin derivatives, aloe gel, sodium lactate, urea, urea derivatives, polymers, and copolymers.

9. The pharmaceutical composition for nasal spray according to claim 8, wherein the nasal spray bottle is part of a retail package consisting essentially of the nasal spray bottle and a separate bottle containing the pharmaceutical composition.

10. A nasal spray system for providing therapeutic relief to a subject suspected of infection or allergy while protecting the nasal mucosa from oxidative damage caused by redox reactions, comprising: A nasal spray bottle configured to deliver aerosolized droplets of 100 microns or less in size generated by a pharmaceutical composition having a viscosity of 1.1-1,000 centipoise, and comprising: Hydrogen peroxide 0.5%-3% w / w; Skin moisturizer 0.1%-30% w / w; Aromatic compounds; and Deionized water, Characterized in that the aerosolized droplets, when applied to the nasal cavity, form a substantially self-adhesive reactive coating with a thickness of less than 0.5 mm on the nasal mucosa, thereby being capable of oxidizing at least a portion of the mucus of the nasal mucosa between 10 and 180 seconds, thereby being capable of loosening the at least a portion of the mucus for removal from the nasal cavity, and simultaneously being capable of dispersing the skin moisturizer, the aromatic compound and the deionized water into the nasal mucosa of the nasal cavity by the energy of the redox reaction between the hydrogen peroxide and the at least a portion of the mucus.

11. The nasal spray system according to claim 10, wherein the skin moisturizer is at least one of the following substances: glycerol and its derivatives.

12. The nasal spray system of claim 10, wherein the skin moisturizer is at least one of the following: a polymer, a copolymer, aloe vera gel, a pharmaceutically acceptable moisturizer, and a pharmaceutically acceptable thickener.

13. The nasal spray system of claim 10, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable heterocyclic compound.

14. The nasal spray system of claim 10, wherein the pharmaceutical composition further comprises 5%-50% v / v alcohol.

15. The nasal spray system of claim 10, wherein the pharmaceutical composition further comprises at least one of chlorhexidine gluconate (CHG) 0.01%-0.1% w / w, cetylpyridinium chloride 0.01%-0.1% w / w, a surfactant, and an astringent.

16. The nasal spray system of claim 10, wherein the pharmaceutical composition further comprises at least one of the following: borax, boric acid, magnesium sulfate, alum, and a pharmaceutically acceptable sodium salt.

17. The nasal spray system of claim 10, wherein the nasal spray bottle is part of a retail package comprising the nasal spray bottle and a bottle containing the pharmaceutical composition.

18. A method of disinfecting the mucous membranes of a subject suspected of infection or allergy by the energy of a redox reaction while protecting said mucous membranes from damage caused by said redox reaction and while providing therapeutic relief, the method essentially comprising: Aerosolized droplets of less than 100 microns in size are sprayed onto the mucous membranes of a subject in need of treatment for infection or allergy using a directional spray bottle configured to deliver a pharmaceutical composition having a viscosity of 1.1-1,000 centipoise, the pharmaceutical composition consisting essentially of the following ingredients: Hydrogen peroxide 0.5%-5% w / w; Skin moisturizer 0.1%-30% w / w; One or more pharmaceutically acceptable heterocyclic compounds 0.005%-2.5% w / w; and Deionized water, It is characterized in that when the aerosolized droplets are applied to the mucosa, a substantially self-adhesive reactive coating with a thickness of less than 0.5 mm is formed on the mucosa, and the body fluid of the mucosa is gradually oxidized between 10 and 180 seconds, thereby loosening the body fluid from the mucosa, and at the same time, the skin moisturizer, the one or more heterocyclic compounds and the deionized water are transported to the mucosa by the energy of the redox reaction between the hydrogen peroxide and the body fluid.

19. The mucosal disinfection method according to claim 18, wherein the skin moisturizer is at least one of the following substances: glycerin, glycerin derivatives, aloe vera gel, polymers, copolymers, sodium lactate, urea and urea derivatives.

20. The method for disinfecting mucous membranes of claim 18, wherein the pharmaceutical composition also consists essentially of 5%-70% alcohol.

21. The method of mucosal disinfection of claim 18, wherein the pharmaceutical composition further consists essentially of at least one of the following: chlorhexidine gluconate (CHG), cetylpyridinium chloride, a cationic surfactant, and an astringent.

22. The method of mucosal disinfection of claim 18, wherein the pharmaceutical composition further consists essentially of at least one of the following: borax, magnesium sulfate, alum, and sodium salt.

23. The method of mucosal disinfection according to claim 22, wherein the pharmaceutical composition also consists essentially of at least one of the following substances: 5%-70% alcohol, chlorhexidine gluconate (CHG), cetylpyridinium chloride, a cationic surfactant and an astringent, and The skin moisturizer is at least one of the following substances: glycerin, glycerin derivatives, aloe gel, polymers, copolymers, sodium lactate, urea, and urea derivatives.

24. The method for disinfecting mucous membranes according to claim 23, wherein the directional spray bottle is part of a retail package consisting essentially of the directional spray bottle and a bottle containing the pharmaceutically acceptable compound.

25. A method of removing mucus from a nasal cavity by the energy of a redox reaction while protecting the mucous membrane of the nasal cavity from damage caused by the redox reaction and providing therapeutic relief, the method comprising: Use the nasal spray bottle to spray the nasal spray into the nasal cavity of the patient who needs to treat infection or allergy. The nasal spray bottle produces aerosolized droplets with a size of less than 100 microns from a pharmaceutical composition, the pharmaceutical composition comprising: Hydrogen peroxide 0.5%-3% w / w; Skin moisturizer 0.1%-30% w / w; One or more aromatic compounds 0.005%-1% w / w; and Deionized water, It is characterized in that when the aerosolized droplets are applied into the nasal cavity, a substantially self-adhesive reactive coating with a thickness of less than 0.5 mm is formed on the mucosa, and at least a portion of the mucus of the mucosa is gradually oxidized between 10 and 180 seconds, thereby loosening the at least a portion of the mucus on the mucosa of the nasal cavity for removal, and at the same time, the skin moisturizer, the aromatic compound and the deionized water can be transported to the mucosa through the redox reaction between the hydrogen peroxide and the at least a portion of the mucus.

26. The method of removing mucus from the nasal cavity according to claim 25, wherein the nasal spray bottle is part of a retail package consisting essentially of the nasal spray bottle and the pharmaceutical composition contained in a separate bottle.

27. A nasal spray, characterized in that: The method comprises using a nasal spray bottle to spray a pharmaceutical composition into a fine mist spray of aerosolized droplets with a particle size of less than 100 microns, wherein the pharmaceutical composition comprises: One or more aromatic compounds 0.005%-1% w / w; Hydrogen peroxide 0.5% to 2.5%; Glycerin, aloe vera gel, pharmaceutically acceptable polymers or combinations thereof 0.1% to 30% w / w; and Deionized water.

28. The nasal spray of claim 27, wherein the nasal spray bottle is part of a retail package comprising the nasal spray bottle and the pharmaceutical composition contained in a separate bottle.

29. A method for delivering a drug through a nasal mucosa using energy from a redox reaction while protecting the nasal mucosa from damage by the energy from the redox reaction, the method comprising: The nasal spray bottle is configured to deliver aerosolized droplets of 100 microns or less in size from the drug component; The pharmaceutical composition comprises: Hydrogen peroxide 0.5%-2.5% w / w; Skin moisturizer 0.1%-30% w / w; One or more pharmaceutically acceptable heterocyclic compounds 0.005%-2.5% w / w; and Deionized water, injecting the aerosolized liquid droplets into the nasal cavity; It is characterized in that when the aerosolized droplets are applied into the nasal cavity, a substantially self-adhesive reactive coating with a thickness of less than 0.5 mm is formed on the nasal mucosa, and at least a portion of the mucus of the nasal mucosa is gradually oxidized between 10 and 180 seconds, thereby loosening the at least a portion of the mucus on the nasal mucosa of the nasal cavity for removal, and at the same time, the skin moisturizer, the aromatic compound and the deionized water are transported to the nasal mucosa by the energy of the redox reaction between the hydrogen peroxide and the mucus.

30. A system for delivering drugs through mucosal membranes using the energy of redox reactions while protecting the mucosal membranes from oxidative damage by the energy of redox reactions, the system consisting essentially of: Retail packaging, mainly including: Directional spray bottles for spraying aerosolized droplets of drug ingredients 100 microns or less in size; and a container containing the pharmaceutical composition, The pharmaceutical composition is mainly composed of the following ingredients: Hydrogen peroxide 0.5%-2.5% w / w; Skin moisturizer 0.1%-30% w / w; One or more pharmaceutically acceptable heterocyclic compounds 0.005%-2.5% w / w; and Deionized water, wherein the aerosolized droplets are formulated to form a substantially self-adherent reactive coating having a thickness of less than 0.5 mm when applied using the directional spray bottle, The reactive coating gradually oxidizes the body fluid on the mucosa within 10 to 180 seconds, thereby loosening the body fluid from the mucosa, and simultaneously transports the skin moisturizer, the heterocyclic compound and the deionized water to the mucosa through the energy of the redox reaction between the hydrogen peroxide and the body fluid.

31. The drug delivery system of claim 30, wherein the drug composition further consists essentially of at least one of the following: alcohol, flavoring agents, surfactants, preservatives, chemical stabilizers, chlorhexidine gluconate (CHG), cetylpyridinium chloride, and astringents.

32. The drug delivery system of claim 30, wherein the drug composition further consists essentially of at least one of the following: borax, magnesium sulfate, alum, and a pharmaceutically acceptable sodium salt.

Images